Mahesh Kumar Posa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahesh Kumar Posa has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Gaurav Tiwari
PSIT-Pranveer Singh Institute of Technology (Pharmacy), Kalpi Road, Bhauti, Kanpur-208020, India
2 shared publications - Aakriti Garg
Department of Pharmacology, Jamia Hamdard School of Pharmaceutical Education and Research, New Delhi, India
1 shared publication - Abdul Lathiff1 shared publication
Aina Bansal
Department of Pharmacology, School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, Jaipur, Rajasthan, India
1 shared publicationAkshay Kulthe
Department of Pharmaceutics, Faculty of Pharmacy, Hon, Shri Babanrao Pachpute Vichardhara Trust’s Group of Institutions, Kashti, Ta- Shrigonda, Ahilyanagar, India
1 shared publication- Anasuya Patil
Department of Pharmaceutics, KLE College of Pharmacy
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 15 (6) , 1194-1200
Clinical profile, serological patterns and treatment outcomes of dengue fever: a prospective cohort study at a tertiary care university hospital
Background: Dengue fever, a globally significant mosquito borne viral infection, exhibits a wide spectrum of clinical manifestations, yet gender specific variations in its presentation and outcomes remain underexplored. We conducted a prospective observational study at Jaipur National University Institute for Medical Sciences and Research Centre, enrolling 50 confirmed dengue patients to evaluate demographic, clinical, and serological differences between genders. Methods: The cohort comprised 62% females and 38% males, with fever (90%), generalized weakness (54%), and myalgia (44%) as the most common symptoms. Hematological involvement was predominant (92%), followed by hepatic (54%) and respiratory (28%) systems. Serological analysis revealed IgM as the most detected marker (50%), while thrombocytopenia (92%) and hepatomegaly (34%) were frequent comorbidities. Results: Notably, gender-based differences emerged, with females exhibiting significantly higher IgG seropositivity (p=0.026) and lower hemoglobin levels (p=0.011) compared to males. Treatment regimens were largely supportive, including pantoprazole (98%), paracetamol (84%), and ondansetron (66%). Our findings highlight the critical role of early hematological and serological monitoring in identifying severe cases, while underscoring the need for gender specific considerations in dengue management. Conclusions: The study provides novel insights into the interplay between gender and disease manifestations, offering actionable evidence to refine clinical protocols and public health strategies in endemic regions. These results emphasize the importance of tailored interventions to mitigate complications and improve patient outcomes.
- 26 October 2026
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 15 (6) , 1194-1200
Open AccessClinical profile, serological patterns and treatment outcomes of dengue fever: a prospective cohort study at a tertiary care university hospital
Background: Dengue fever, a globally significant mosquito borne viral infection, exhibits a wide spectrum of clinical manifestations, yet gender specific variations in its presentation and outcomes remain underexplored. We conducted a prospective observational study at Jaipur National University Institute for Medical Sciences and Research Centre, enrolling 50 confirmed dengue patients to evaluate demographic, clinical, and serological differences between genders. Methods: The cohort comprised 62% females and 38% males, with fever (90%), generalized weakness (54%), and myalgia (44%) as the most common symptoms. Hematological involvement was predominant (92%), followed by hepatic (54%) and respiratory (28%) systems. Serological analysis revealed IgM as the most detected marker (50%), while thrombocytopenia (92%) and hepatomegaly (34%) were frequent comorbidities. Results: Notably, gender-based differences emerged, with females exhibiting significantly higher IgG seropositivity (p=0.026) and lower hemoglobin levels (p=0.011) compared to males. Treatment regimens were largely supportive, including pantoprazole (98%), paracetamol (84%), and ondansetron (66%). Our findings highlight the critical role of early hematological and serological monitoring in identifying severe cases, while underscoring the need for gender specific considerations in dengue management. Conclusions: The study provides novel insights into the interplay between gender and disease manifestations, offering actionable evidence to refine clinical protocols and public health strategies in endemic regions. These results emphasize the importance of tailored interventions to mitigate complications and improve patient outcomes.
- Open Access
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Precision Medicine in Neurodegenerative Disorders: Integrating Biomarkers, Gene Therapy, Immunotherapy, Neuromodulation, and AI for Personalized Treatment
The NDD's are characterized by progressive loss of neurons and cognitive or locomotor dysfunction, which pose significant challenges due to the complexity of their etiology and the diversity of clinical manifestations. We suggest a precision medicine system that combines multimodal biomarkers, innovative therapeutic methods, and artificial intelligence (AI) to obtain personalized diagnosis and treatment. Genetic and transcriptomic biomarkers with cerebrospinal fluid ones, such as polygenic risk scores and abnormal microRNAs, are combined with blood-based ones to enhance scalability and minimize invasiveness. The treatments are gene therapy, which is designed to treat genetic defects through editing, suppressing or inserting procedures, and immunotherapy, which is supposed to address the abnormal protein deposits including tau and amyloid-beta. In addition, neuromodulation techniques like transcranial magnetic stimulation and transcranial direct current stimulation are used to restore brain activity in the damaged regions of the brain. To identify biomarkers and monitor disease progression, AI and machine learning models, e.g., convolutional neural networks and support vector machines, analyze diverse types of data, including neuroimaging and wearable sensor data. The suggested framework addresses the flaws of the traditional approaches through a holistic and evidence-based approach tailored to the unique features of every patient. This combination not only improves the precision of the diagnosis but also the result of the treatment and thus improves the field of specialized medicine in neurodegenerative diseases.
- 21 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPrecision Medicine in Neurodegenerative Disorders: Integrating Biomarkers, Gene Therapy, Immunotherapy, Neuromodulation, and AI for Personalized Treatment
The NDD's are characterized by progressive loss of neurons and cognitive or locomotor dysfunction, which pose significant challenges due to the complexity of their etiology and the diversity of clinical manifestations. We suggest a precision medicine system that combines multimodal biomarkers, innovative therapeutic methods, and artificial intelligence (AI) to obtain personalized diagnosis and treatment. Genetic and transcriptomic biomarkers with cerebrospinal fluid ones, such as polygenic risk scores and abnormal microRNAs, are combined with blood-based ones to enhance scalability and minimize invasiveness. The treatments are gene therapy, which is designed to treat genetic defects through editing, suppressing or inserting procedures, and immunotherapy, which is supposed to address the abnormal protein deposits including tau and amyloid-beta. In addition, neuromodulation techniques like transcranial magnetic stimulation and transcranial direct current stimulation are used to restore brain activity in the damaged regions of the brain. To identify biomarkers and monitor disease progression, AI and machine learning models, e.g., convolutional neural networks and support vector machines, analyze diverse types of data, including neuroimaging and wearable sensor data. The suggested framework addresses the flaws of the traditional approaches through a holistic and evidence-based approach tailored to the unique features of every patient. This combination not only improves the precision of the diagnosis but also the result of the treatment and thus improves the field of specialized medicine in neurodegenerative diseases.
- Open Access
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Comprehensive Review of Nipah Virus Outbreaks and Cases: Epidemiology, Clinical Manifestations, Diagnostic approaches and Therapeutic Advances in Nipah Virus Treatment
Nipah virus (NiV) infections have become a major public health issue in India, as sporadic outbreaks lead to high mortality and generate widespread fear owing to the virus's zoonotic nature and absence of effective treatments. This comprehensive review examines and consolidates current data on NiV outbreaks in India, with attention directed toward three primary aspects: the epidemiology of outbreaks, diagnostic methods and immune reactions, One Health model for public health intervention and the latest advances in Nipah virus vaccine development. We conducted a comprehensive analysis of peer-reviewed literature to identify patterns in NiV transmission, clinical presentation, and containment strategies, thereby addressing critical gaps in understanding the virus's behavior in the Indian context. The results indicate that NiV outbreaks in India are marked by localized zoonotic spillovers, frequently associated with fruit bats, subsequently leading to human to human transmission in healthcare environments, where case fatality rates can rise above 70% in certain cases. Symptoms vary from acute encephalitis to severe respiratory distress, yet diagnostic difficulties remain because of inadequate infrastructure in affected areas. Public health measures have changed over the years, but deficiencies still exist in monitoring, public involvement, and cross-disciplinary collaboration within the One Health framework. The review underscores the urgent need for strengthened outbreak preparedness, improved diagnostic capacity, and targeted research into therapeutics and vaccines. This work synthesizes existing knowledge, establishing a basis for subsequent research and policy actions aimed at reducing the threat of NiV in India and other regions.
- 23 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessComprehensive Review of Nipah Virus Outbreaks and Cases: Epidemiology, Clinical Manifestations, Diagnostic approaches and Therapeutic Advances in Nipah Virus Treatment
Nipah virus (NiV) infections have become a major public health issue in India, as sporadic outbreaks lead to high mortality and generate widespread fear owing to the virus's zoonotic nature and absence of effective treatments. This comprehensive review examines and consolidates current data on NiV outbreaks in India, with attention directed toward three primary aspects: the epidemiology of outbreaks, diagnostic methods and immune reactions, One Health model for public health intervention and the latest advances in Nipah virus vaccine development. We conducted a comprehensive analysis of peer-reviewed literature to identify patterns in NiV transmission, clinical presentation, and containment strategies, thereby addressing critical gaps in understanding the virus's behavior in the Indian context. The results indicate that NiV outbreaks in India are marked by localized zoonotic spillovers, frequently associated with fruit bats, subsequently leading to human to human transmission in healthcare environments, where case fatality rates can rise above 70% in certain cases. Symptoms vary from acute encephalitis to severe respiratory distress, yet diagnostic difficulties remain because of inadequate infrastructure in affected areas. Public health measures have changed over the years, but deficiencies still exist in monitoring, public involvement, and cross-disciplinary collaboration within the One Health framework. The review underscores the urgent need for strengthened outbreak preparedness, improved diagnostic capacity, and targeted research into therapeutics and vaccines. This work synthesizes existing knowledge, establishing a basis for subsequent research and policy actions aimed at reducing the threat of NiV in India and other regions.
- 17 April 2026
- Published by Elsevier
- p. 179-201
Nanostructures in embryo viability and implantation
- 17 April 2026
- Published by Elsevier
- p. 325-344
Nanotechnology in fertility preservation for cancer patients
- 17 April 2026
- Published by Elsevier
- p. 325-344
Nanotechnology in fertility preservation for cancer patients
- Open Access
- 30 January 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101125
CAR T- cell therapy: A promising novel approach for treatment of cancer
- 30 January 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 47, 101125
Open AccessCAR T- cell therapy: A promising novel approach for treatment of cancer
- 18 June 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 35 (13) , 2068-2089
Design, optimization, and evaluation of methotrexate loaded and albumin coated polymeric nanoparticles
Methotrexate is a potent anticancer drug whose strong efflux is facilitated by the brain's efflux transporter. As an efflux transporter blocker, albumin increased the drug's concentration in the brain. Methotrexate-loaded nanoparticles were produced by evaporating the emulsification fluid. Improvements and analyses were made to the following aspects of the generated nanoparticles: size, polydispersity, zeta potential, entrapment efficiency, percentage yield, scanning electron microscopy, in vitro drug release studies, and sterilization. The particle size was determined to be in the nano range, and homogeneity of particle size was suggested by a low polydispersity index result. Particle diameters of 168 nm were observed in the F5 preparation, and zeta potential values of -1.5 mV suggested that the preparation produced adequate repulsive interactions between the nanoparticles. Albumin and dopamine HCl were employed to coat the methotrexate-loaded nanoparticles to guarantee that the brain received an adequate amount of them. The homogeneity of albumin coated nanoparticles was demonstrated by the low% PDI values of 0.129 and 0.122 for albumin coated nanoparticles (MNPs-Alb) and polymerized dopamine HCl and albumin coated nanoparticles (MNPs-PMD-Alb), respectively. After 48 h of incubation, the cell viability measured at the same drug concentration (5 mg) decreased for the F5, albumin coated nanoparticles, polymerized dopamine HCl coated nanoparticles, and polymerized dopamine HCl and albumin coated nanoparticles, respectively. Our primary findings demonstrate that the albumin nanoparticles containing methotrexate are designed to deliver the drug gradually. With minimal cytotoxicity, the intended preparation might give the brain an appropriate dosage of methotrexate.
- 18 June 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 35 (13) , 2068-2089
Design, optimization, and evaluation of methotrexate loaded and albumin coated polymeric nanoparticles
Methotrexate is a potent anticancer drug whose strong efflux is facilitated by the brain's efflux transporter. As an efflux transporter blocker, albumin increased the drug's concentration in the brain. Methotrexate-loaded nanoparticles were produced by evaporating the emulsification fluid. Improvements and analyses were made to the following aspects of the generated nanoparticles: size, polydispersity, zeta potential, entrapment efficiency, percentage yield, scanning electron microscopy, in vitro drug release studies, and sterilization. The particle size was determined to be in the nano range, and homogeneity of particle size was suggested by a low polydispersity index result. Particle diameters of 168 nm were observed in the F5 preparation, and zeta potential values of -1.5 mV suggested that the preparation produced adequate repulsive interactions between the nanoparticles. Albumin and dopamine HCl were employed to coat the methotrexate-loaded nanoparticles to guarantee that the brain received an adequate amount of them. The homogeneity of albumin coated nanoparticles was demonstrated by the low% PDI values of 0.129 and 0.122 for albumin coated nanoparticles (MNPs-Alb) and polymerized dopamine HCl and albumin coated nanoparticles (MNPs-PMD-Alb), respectively. After 48 h of incubation, the cell viability measured at the same drug concentration (5 mg) decreased for the F5, albumin coated nanoparticles, polymerized dopamine HCl coated nanoparticles, and polymerized dopamine HCl and albumin coated nanoparticles, respectively. Our primary findings demonstrate that the albumin nanoparticles containing methotrexate are designed to deliver the drug gradually. With minimal cytotoxicity, the intended preparation might give the brain an appropriate dosage of methotrexate.
- Open Access
- 3 December 2023
- Published by Elsevier in Health Sciences Review
- Vol. 10
Oroxylin A: Nature's arsenal against liver fibrosis, cancer, and inflammatory diseases
- 3 December 2023
- Published by Elsevier in Health Sciences Review
- Vol. 10
Open AccessOroxylin A: Nature's arsenal against liver fibrosis, cancer, and inflammatory diseases
- Open Access
- 18 May 2023
- Published by Elsevier in Health Sciences Review
- Vol. 7, 100099
Diabetes and deaths of COVID-19 patients: Systematic review of meta-analyses
- 18 May 2023
- Published by Elsevier in Health Sciences Review
- Vol. 7, 100099
Open AccessDiabetes and deaths of COVID-19 patients: Systematic review of meta-analyses